Brief: Celltrion Inc To Provide 176 Billion Won Worth Of Biosimilar Drugs
28/06/2022 01:28
June 28 (Reuters) - Celltrion Inc 068270.KS :
* TO PROVIDE 176 BILLION WON WORTH OF BIOSIMILAR DRUGS
Further company coverage: 068270.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares